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Abstract The adhesive protein vitronectin (75 kDa) occurs in
human blood fluid in a one-chain (Vn75) or a two-chain form
(Vn6510), and is produced by a specific cleavage (at Arg379^
Ala380), by a proteinase not identified hitherto. These two forms
were shown to be functionally different and therefore, this
cleavage may have a regulatory significance in vivo. Here, we
report the use of a tailored one-chain recombinant Vn, a specific
protein kinase A phosphorylation at Ser378, and sequence
analysis to show: (1) that none of the proteinases originating
from blood, previously thought to be the endogenous proteinase
(plasmin, thrombin, tPA, and uPA), is indeed the in vivo
convertase; and (2) that furin, a serine endoproteinase residing in
the secretory pathway of hepatocytes, where Vn is synthesized,
specifically cleaves Vn at the endogenous cleavage site. Conse-
quently, we propose that the Vn75 to Vn6510 conversion takes
place in the liver (not in blood) and is carried out by
furin. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vitronectin (Vn) was discovered as a ‘serum spreading fac-
tor’ [1] ; however, it is now considered to be not only an
important adhesive glycoprotein in the extracellular matrix,
and in circulating blood, but also an important participant
in a large variety of other biological functions. These include
cell attachment, spreading and migration, blood coagulation,
plasminogen activation, ¢brinolysis, and the regulation of
complement function ([2^5] and references therein).
Vn is present in human blood £uid at concentrations of
200^400 Wg/ml, and therefore constitutes 0.2^0.5% of the total
plasma proteins. Reduced plasma levels of Vn have been re-
ported in patients with severe liver failure, suggesting that the
liver is the major source of Vn in plasma [6,7].
In circulating blood, Vn is found in two molecular forms: a
one-chain form of 75 kDa (Vn75) and a clipped form (Vn6510)
composed of two chains (65 and 10 kDa) held together by a
disul¢de bridge [8]. The two forms seem to be the product of
distinct genes, that di¡er in a single amino acid at position
381. Methionine at this position gives rise to the V75 form,
whereas threonine gives rise to a cleavage in vivo (at Arg379^
Ala380), and yields the Vn6510 form [9].
Since evidence was presented to show that Vn is secreted
from Hep G2 cells as a single chain glycoprotein [10], it
seemed reasonable to assume that this cleavage takes place
in blood £uid. Several blood proteinases were proposed to
carry out the Arg379^Ala380 cleavage, however, none of them
was rigorously demonstrated (by sequence analysis) to be the
endogenous proteinase that carries out the cleavage in vivo.
Consequently, the locus of the endogenous cleavage was not
established unequivocally.
Our interest in establishing the identity of this endogenous
proteinase stemmed from our ¢nding that this endogenous
cleavage yields a functionally distinct form of Vn. For exam-
ple, we found that under physiological conditions, Vn6510 has
a higher a⁄nity for heparin [11], and a di¡erent heparin de-
pendence in its phosphorylation by protein kinase A (PKA)
[12].
Here we show that furin, a serine endoproteinase which
resides in the secretory pathway of hepatocytes selectively
cleaves this bond, and propose that the conversion of Vn75
to Vn6510 takes place in the liver (prior to secretion) and not
in blood, as suggested hitherto.
2. Materials and methods
2.1. Chemicals and enzymes
The following materials were purchased from the commercial sour-
ces: heparin Sepharose, plasmin, and K-thrombin from Sigma; [Q-
32P]ATP (3000 Ci/mmol), and [35S]methionine from Amersham; nitro-
cellulose membranes from Schleicher and Schuell; t-PA, and u-PA
were purchased from Calbiochem; recombinant N-glycanase from
Genzyme diagnostics, furin was purchased from A⁄nity Bioreagents
(ABR).
2.2. Other proteins and enzymes
Vn was puri¢ed from freshly frozen human plasma as described
previously [8] with the modi¢cations used routinely in our laboratory
[11,13]. The catalytic subunit of PKA was puri¢ed according to the
method described by Beavo [14].
2.3. Expression and puri¢cation recombinant Vn
The Vn(Thr-381) was expressed as described previously [15]. The
expressed protein was collected from medium of High-5 infected cells
and loaded on a heparin agarose column previously equilibrated with
150 mM NaCl/50 mM Tris^HCl (pH 7.5), all at 4‡C. The column was
washed with the same bu¡er and fractions were eluted by a gradient
of 150 mM to 1 M NaCl in Tris^HCl (pH 7.5). Eluted fractions were
analyzed by immunoblotting and by silver staining. Samples of the
peak were pooled and concentrated on centrifugal membrane ¢lter
device (Millipore), yielding a pure and concentrated Vn(Thr-381)
(0.5^1 mg/ml, as determined by the Pierce protein assay).
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2.4. Cleavage of Vn(Thr-381) by various blood proteinases (thrombin,
plasmin, u-PA, or by t-PA)
The reaction mixture (180 Wl) contained the following constituents
at the indicated ¢nal concentrations: Vn (27 Wg/ml), HEPES bu¡er
(50 mM), pH 7.5, and one of the proteinases as follows; thrombin
(17.5 U/ml), plasmin (1.7 Wg/ml), u-PA, t-PA (200 IU in 240 Wl). Each
reaction was allowed to proceed at 37‡C for the time periods indicated
in the appropriate ¢gure legend.
2.5. Cleavage of Vn(Thr-381) by furin
The reaction mixture (total volume 100 Wl) contained the following
constituents at the indicated ¢nal concentrations: Vn(Thr-381) (20 Wg/
ml), HEPES bu¡er (100 mM), pH 7.5, CaCl2 (2 mM), L-mercapto-
ethanol (1 mM), octyl-L-D-glucopyranoside (0.1%), and furin (100 U/
ml). The reaction was allowed to proceed at 30‡C for 20 h. Aliquots
were removed and analyzed by PKA phosphorylation (which occurs
speci¢cally at Ser378) and SDS^PAGE with Coomassie blue staining in
order to identify the cleavage products. The experimental conditions
used for the cleavage were adopted from [16]. It should be noted that
the prolonged incubation with Vn was necessary to obtain the extent
of cleavage needed for analysis of the cleavage products, presumably
due to the fact that the enzyme we used is a recombinant protein, and,
as such, it might not be optimally folded. It might also be due to the
fact that furin resides in the cell in a membranal milieu which we
might not adequately simulate in aqueous solution.
2.6. Phosphorylation of Vn(Thr-381) by PKA
The phosphorylation assay mixture (50 Wl) contained the following
constituents at the indicated ¢nal concentrations: Vn(Thr-381) (11 Wg/
ml), the C-subunit of PKA (3 Wg/ml), magnesium acetate (20 mM),
[Q32P]ATP (10 WM; 6 Ci/mmol), HEPES bu¡er (20 mM, pH 7.5), and
heparin (10 Wg/ml). The reaction was allowed to proceed at room
temperature for 30 min and was arrested by the addition of 17 Wl
of 4U concentrated Laemmli’s sample bu¡er and boiling for 3 min.
Thereafter, the samples were subjected to SDS^PAGE, the gels were
then dried and exposed to radiography.
2.7. Western blots analysis of Vn(Thr-381)
The blots were probed with polyclonal K-Vn antiserum, followed by
goat anti-rabbit IgG conjugated to horseradish peroxidase. The bands
were visualized by ECL.
2.8. Sequencing the 10-kDa band produced by furin cleavage of
Vn(Thr-381)
Furin-cleaved Vn(Thr-381) was run on 12.5% PAGE previously
pre-run for 10 min using 5 mM sodium thioglycolate in the running
bu¡er. The gel was transferred to a PVDF membrane using a Bio-Rad
wet transfer apparatus. The bands were visualized by light Coomassie
blue staining (in 50% methanol and 5% acetic acid, for 5^10 min)
followed by destaining in 50% methanol. The 10-kDa band, excised
from the dried membrane, was sequenced in a Procise protein se-
quencer 491, from Applied Biosystems.
2.9. Preparation of the Vn(1^379) mutant, and of the Vn(S378A)
mutant
The Vn(1^379) mutant was generated by inserting a stop codon
after R379. Taking advantage of the two Msc1 sites (332 base pair
apart) a PCR fragment was generated using a sense oligonucleotide
upstream from the ¢rst Msc1 site and an antisense oligonucleotide
downstream the second Msc1 site which contained a TAA stop codon
insertion (underlined). The antisense oligonucleotide sequence was:
5P-GGA TGG CCA CGT TTA GCG GGA TGG CCG-3P. The
PCR product was digested with Msc1 and subcloned into Msc1 di-
gested Vn(Thr-381)-pRSET.
The S378A point mutation in Vn was generated by PCR ampli¢-
cation using Vn(Thr-381) cDNA (in pGEX 2T) as a template. The
sense oligonucleotide was: 5P-TCC CGC CGG CCA GCC CGC
GCC-3P. The antisense oligonucleotide designed from the vector-
pGEX 2T was: 5P-CGT CAG TCA GTC ACG ATG AAT TC-3P.
Puri¢ed PCR-ampli¢ed fragments digested with NaeI and EcoRI were
ligated into Vn(Thr-381)-pGEX-2T digested with NaeI and EcoRI.
Both constructs were sequenced in order to con¢rm that the ampli¢-
cation was correct, before further subcloning into the PVL 1393 trans-
fer vector (BamHI and EcoRI sites). Forced recombination into the
viral DNA and further procedures for the expression were carried out
as described earlier [15].
3. Results and discussion
3.1. Expression, characterization and puri¢cation of the
Vn(Thr-381) used in this study
To identify the endogenous proteinase that clips Vn at the
Arg379^Ala380 bond, we prepared a recombinant Vn contain-
Fig. 1. Puri¢cation and characterization of Vn(Thr-381) expressed in
a baculovirus system. (A) Expression of Vn(Thr-381) in High-5 in-
sect cells : Vn was expressed in baculovirus infected High-5 cells.
Samples of medium containing secreted Vn(Thr-381) were analyzed
by immunoblot using anti-human Vn polyclonal antibodies. Vn(Thr-
381) (lane 3); medium of non-infected High-5 cells (lane 2); and Vn
puri¢ed from human plasma (lane 1). (B) Deglycosylation of plasma
Vn, and of Vn(Thr-381) expressed in High-5 cells. Medium of a
sample containing secreted Vn(Thr-381) (lane 1), or a sample of Vn
(lane 2), puri¢ed from plasma. Samples (0.5 Wg of each) were dena-
tured at 56‡C for 15 min then treated with 1 U of N-glycanase in
100 mM Tris bu¡er, pH 8.6 (total reaction mixture 100 Wl) for 2 h
at 37‡C. The samples were analyzed by immunoblotting using anti-
human Vn polyclonal antibodies. (C) Puri¢cation of Vn(Thr-381)
expressed in High-5 insect cells. Vn(Thr-381) collected from medium
of High-5 infected cells was loaded on a heparin agarose column
previously equilibrated with 150 mM NaCl/50 mM Tris^HCl (pH
7.5), all at 4‡C. Thereafter the column was washed with the same
bu¡er and fractions were eluted by a gradient of 150 mM to 1 M
NaCl in a Tris^HCl bu¡er (pH 7.5). Aliquots from the indicated
fractions were boiled (5 min in Laemmli’s sample bu¡er) and loaded
on SDS^PAGE (10% acrylamide). The gels were analyzed by silver
staining (top gel), and by immunoblotting with anti-Vn polyclonal
antibodies (bottom gel). p, put on; w, wash through.
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ing Thr at position 381 (Vn(Thr-381)), as in the physiological
precursor of the two-chain form of Vn. This recombinant Vn
(MW V70 kDa (Fig. 1A)) was expressed in High-5 insect
cells and secreted into the growing medium using its own
signal peptide. The secreted protein was found to be a one-
chain protein, with a reduced molecular size (70 instead of 75
kDa) most likely due to an incomplete glycosylation in the
insect cells. Indeed, upon enzymatic deglycosylation, both the
Vn(Thr-381) we prepared, and the one-chain form of Vn (75
kDa) isolated from plasma, were found to co-migrate when
run alongside (Fig. 1B). Therefore, the recombinant Vn that
contains a Thr residue at position 381 and is not clipped in
the High-5 cells is a suitable substrate for the identi¢cation of
the endogenous proteinase that cleaves Vn at its Arg379^Ala380
bond. The Vn(Thr-381) we collected from infected high-5 cells
medium was puri¢ed on a heparin agarose column, and the
eluted fractions were analyzed by immunoblotting and by
silver staining and shown to be pure (Fig. 1C). The samples
from the peak fractions were pooled and concentrated to
0.5^1 mg/ml as described in Section 2.
Fig. 2. Identi¢cation of the Vn cleavage products following digestion by proteinases originating from blood £uid. (A) Monitoring the plasmin
cleavage. Vn(Thr-381), or Vn(S378A) mutant were digested with plasmin (for details, see Section 2). The cleavage products were revealed by
PKA phosphorylation (one site in Vn at Ser378) which was carried out at 22‡C for 30 min in the presence of [Q32P]ATP. The reaction was ter-
minated by boiling for 5 min in Laemmli’s sample bu¡er and loading on SDS^PAGE (10% acrylamide). The gels were dried and exposed to
autoradiography (top gel) or transferred to nitrocellulose membranes and blotted (bottom gel) using human anti-Vn polyclonal antibodies. (B)
Monitoring the thrombin digestion. Vn(Thr-381) was digested by thrombin (for details, see Section 2). The cleavage products were revealed as
described in A. (C) Monitoring the u-PA and t-PA digestion. Vn(Thr-381) was digested by u-PA or t-PA (for details, see Section 2). The cleav-
age products were revealed as described in A.
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3.2. Vn(Thr-381) is not cleaved by proteinases found in blood
Based on the approximate MW of the cleavage products
obtained from plasma Vn by some basophilic proteinases it
was assumed that either plasmin, tPA, or uPA might be the
natural endogenous proteinase responsible for the cleavage of
the Arg379^Ala380 bond in Vn. The identi¢cation and charac-
terization of this endogenous proteinase further attracted our
attention when we found that the one-chain and the two-chain
forms of Vn di¡er in their properties in a way that might
imply a di¡erence in their physiological function [11,12] and
have a distinct regulatory role in blood. If so, the proteinase
might even constitute an interesting pharmacological target.
The determination of the locus in which this cleavage occurs
(blood itself as assumed hitherto, or liver where the biosyn-
thesis of Vn is known to take place) is also important in that
respect.
In our search for the endogenous proteinase, we used: (1) a
one-chain recombinant Vn containing Thr at position 381
(Vn(Thr-381)) as in the natural precursor of the two-chain
Vn form, as well as a truncated Vn at the endogenous site
(Vn(1^379) and a single-site mutated Vn (Vn(S378A)); (2) the
selective phosphorylation of Ser-378 with PKA; (3) the con-
sensus sequence for the cleavage site of each proteinase; and
(4) a rigorous determination of the exact cleavage site of each
suspected proteinase by amino acid sequencing or by mass
spectrometry of the cleavage products, and not only by deter-
mining the approximate molecular size of the cleavage prod-
uct(s) using SDS^PAGE.
We have previously shown that plasmin cleaves the Vn
found in blood £uid at the Arg361^Ser362 bond yielding a
12-kDa radiolabeled fragment [17]. However, we considered
the possibility that all the cleavable Vn in blood with a Thr at
position 381 had already been clipped and that the plasmin
cleavage at the Arg361^Ser362 bond that yielded the 12-kDa
radiolabeled fragment represents the plasmin cleavage of the
Vn molecules having a Met at position 381 (to investigate
possibility that plasmin also cleaves at Arg379^Ala380, we
needed a one chain Vn having a Thr at position 381
(Vn(Thr-381)). If plasmin cleaves this Vn at Arg379^Ala380,
we should get a 2-kDa radiolabled band of the phosphopep-
tide 361^379, rather than the 12-kDa fragment of the segment
362^459 (see Scheme 1A for size prediction).
Scheme 1. Schematic presentation of the cleavage sites and localization of the proteolytic fragments generated following exposure to blood-£uid
proteinases and subsequent phosphorylation with PKA at Ser378. (A) The Vn cleavage products generated following plasmin or thrombin cleav-
age. Based on the already known sites of cleavage by plasmin [17] and by thrombin [18], we predicted that the radiolabeled fragments of
cleaved Vn(Thr-381) used in this study should be: a 12-kDa radiolabeled fragment containing residues 362^459 if plasmin does not cleave at
the endogenous cleavage site (Arg379^Ala380) ; and a 2-kDa radiolabeled fragment corresponding to residues 362^379 if plasmin also cleaves at
this site. Similarly, based on the known sites of thrombin cleavage in Vn, we expected to get a 17-kDa radiolabeled fragment originating from
the 305^459 segment in Vn, if thrombin does not cleave the endogenous cleavage site (i.e. the Arg379^Ala380 bond), and only a 7-kDa fragment
corresponding to residues 305^379 in Vn, if thrombin cleaves this site. (B) The Vn cleavage products generated following its digestion with fur-
in. If furin cleaves Vn at the Arg379^Ala380 bond we expect to generate a 60-kDa radiolabled fragment corresponding to the 1^379 segment,
which should contain the PKA phosphorylated Ser378.
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Fig. 2 depicts the exposure of Vn(Thr-381) to four protein-
ases which are activated in blood. It is clearly evident that
while plasmin and thrombin cleave Vn(Thr-381) (Fig. 2A,B),
u-PA and t-PA do not cleave it (Fig. 2C). When Vn(Thr-381)
is exposed to plasmin for increasing time periods, and then
subjected to phosphorylation by PKA, a V12-kDa clipped
product is formed that was found to be radiolabeled by radio-
actively labeled ATP and PKA (Fig. 2A, upper panel). The
phosphorylation of Vn by PKA was previously shown to be
site speci¢c with Vn isolated from plasma [12]. Nevertheless,
this was recon¢rmed here with the recombinant substrate used
in our study, by the demonstration that when Ser-378 is mu-
tated to Ala, it is not phosphorylated at all by PKA (Fig.
2A,B). Since upon cleavage with plasmin the radiolabel is
found in the small fragment (12 kDa) we could conclude
that plasmin does not cleave Vn at the Arg379^Ala380 bond
since the Ser378 phosphorylation site precedes this bond (cf.
Scheme 1).
We have previously shown that thrombin cleaves Vn at
Arg305^Thr306, and at Arg370^Asn371 [18]. If thrombin cleaves
Vn also at the endogenous cleavage site (Arg379^Ala380), we
would expect to get a 7-kDa radiolabled band originating
from the 305^379 segment (see Scheme 1A). Indeed, such a
labeled peptide was formed (Fig. 2B, upper panel). However,
mass-spectrometry analysis of the cleaved fragments indicated
that this peptide was formed as a result of an additional
thrombin cleavage site (at Arg444^Ser445, not reported previ-
ously), that yields a 371^444 radiolabeled peptide.
3.3. Furin selectively cleaves the Arg379^Ala380 bond in Vn
In view of the fact that none of the plasma proteases tested
was able to cleave Vn at the endogenous cleavage site, we
considered the possibility that the proteinase might cleave
Vn already during its production in the liver. We considered
this possibility, in spite of the fact that previous reports in-
dicated that Vn is secreted from hepatoma cells in its single
chain form (MW of 75 kDa [10]). This reconsideration was
based on another report from which one could deduce that
during Vn production in Hep G2, both forms of Vn (the one
chain (Vn75), and the two chain form (Vn6510)) are secreted
[19]. In addition, a similar observation was also made in our
laboratory (Z. Gechtman and S. Shaltiel, unpublished results).
In view of the above, we attempted to establish whether the
cleavage of Vn at Arg379^Ala380 occurs in the liver prior to
secretion, for example by a member of the hepatic family of
proenzyme convertases (PCs), that are known to reside in the
secretory pathway of hepatocytes. The candidate proteinase
chosen was furin, for the following reasons: (1) it was previ-
ously shown to be highly expressed in Hep G2 cells and in
normal hepatocytes [20], and to reside in the trans Golgi net-
work, where it cleaves a wide variety of proenzymes [21] ; (2) it
is commercially available in a recombinant form; and most
importantly, (3) its speci¢city is most appropriate to bring
about the endogenous cleavage of Vn at R376PSRsA380.
It should be noted that the minimal consensus sequence for
cleavage of furin is RXXRs [16], is found at three di¡erent
locations in Vn, (R361SQRsG365, at R376PSRsA380, and at
R431TRRsV435). However, in a study surveying the sequences
of various protein substrates processed constitutively by furin
the cleavage at RsA was found to have a high preference. For
example, out of 34 precursor proteins processed by furin, 10
were cleaved at an Arg^Ala site, only two were cleaved at an
Arg^Gly site, and none was cleaved at an Arg^Val site [22].
Taking advantage of the speci¢c PKA phosphorylation of Vn
at S378, and the fact that the optimal consensus sequence for
furin cleavage is at R376PSRsA380, we expected that if furin is
indeed the endogenous proteinase, the cleavage of Vn(Thr-
381) would yield one radioactively labeled product with a
MW of V60 kDa (the radioactive label originating from
S378). As seen in Fig. 3A (lanes 2 and 3), this is indeed the
case: the cleavage product obtained co-migrated with the
truncated mutant Vn(1^379). To obtain a rigorous identi¢ca-
tion of the cleavage site we searched for the V10 kDa (non-
labeled) cleavage product which should also be formed as a
result of the furin cleavage in order to sequence it and estab-
lish unequivocally the cleavage site. For this purpose, we sub-
jected the reaction mixture to SDS^PAGE and staining with
Coomassie blue, focusing on the low MW products (6 30
kDa). As seen in Fig. 3B after cleavage with furin, we ob-
tained two bands (I and II). Band I had exactly the sequence
corresponding to the free N-terminus which is to be formed as
Fig. 3. Furin cleaves Vn at the Arg379^Ala380 bond, yielding
Vn6510. The recombinant Vn(Thr-381) was digested by furin for
20 h at 30‡C. The cleavage products were revealed (A) by PKA
phosphorylation (as described in Fig. 2) and (B) by Coomassie blue
staining, comparing the low MW bands of Vn(Thr-381). The prod-
ucts of furin digested Vn(Thr-381) (lane 2, A and B) were compared
to Vn(Thr-381) incubated under identical conditions, but without
furin (lane 1, A and B), and to the Vn(1^379) truncated mutant, in
which a stop codon was inserted after the endogenous cleavage site,
to yield the polypeptide segment 1^379 (A, lane 3).
Table 1
Sequence analysis of the 10-kDa band resulting from Vn(Thr-381)
cleavage by furin
Amino acid
position in Vn
Cycle Amino acid
determined
Yield (pmol)
380 1 A 14.0
381 2 T 8.5
382 3 W 0a
383 4 L 13.4
384 5 S 13.5
385 6 L 12.3
386 7 F 7.8
387 8 S 13.3
388 9 S 13.8
389 10 E 7.5
aThe yield was too low for quantitative determination because of
the lability of tryptophan during acid hydrolysis.
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a result of the endogenous cleavage (Table 1). In addition, we
often observed an additional band (Band II in Fig. 3B, lane
2). The relative amount of Band II varied from one experi-
ment to another and our attempts to positively identify its
structure failed so far. However, we found that it has a
blocked N-terminus and, therefore, even if it originates from
Vn, it could not originate from the vicinity of the endogenous
cleavage site (cf. Scheme 1).
3.4. Concluding remarks
The results presented in this report show that none of the
serum proteinases previously proposed to cleave the Arg379^
Ala380 bond is the endogenous proteinase (they all cleave in
the vicinity of this bond, but not at the bond itself). However,
furin, a calcium-dependent serine endoprotease which resides
in the secretory pathway of hepatocytes speci¢cally cleaves
this bond and may thus be the endogenous proteinase respon-
sible for the physiological cleavage of the one-chain into the
two-chain form of Vn. On the basis of these ¢ndings, we
propose that the Vn75 to Vn6510 conversion takes place in
the liver prior to secretion, not in the blood, as hitherto sug-
gested. This ¢nding sets the stage for getting a deeper insight
into the physiological (possibly regulatory) signi¢cance of the
Vn75 to Vn6510 conversion, and identi¢es a potential target
enzyme for pharmacological intervention.
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